- Country: Australia
CSL to pay $2.3b in lixudebart rare disease drug deal with Alentis Therapeutics
CSL has agreed to pay as much as $2.3 billion to jointly develop and sell an experimental treatment for rare kidney and liver diseases, expanding the biotech company’s push into kidney medicine.